<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111330</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PBF-2013-155</org_study_id>
    <secondary_id>2013-005035-25</secondary_id>
    <nct_id>NCT02111330</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) &quot;After Multiple Oral Doses&quot; in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) &quot;After Multiple Oral Doses&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Palo Biofarma, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the safety and tolerability of three doses of PBF-509 (80 mg, 160 mg and 240
      mg) after repeated (8 days) single daily oral dose administration in young male and female
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>day 0-9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile Analysis (Plasma concentrations)</measure>
    <time_frame>day 0-9</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Dose I - 80 mg PBF-509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one 80 mg PBF-509 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose I - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose II - 160 mg PBF-509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 80 mg PBF-509 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose II - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose III - 240 mg PBF-509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three 80 mg PBF-509 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose III - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBF-509</intervention_name>
    <arm_group_label>Dose I - 80 mg PBF-509</arm_group_label>
    <arm_group_label>Dose II - 160 mg PBF-509</arm_group_label>
    <arm_group_label>Dose III - 240 mg PBF-509</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose I - Placebo</arm_group_label>
    <arm_group_label>Dose II - Placebo</arm_group_label>
    <arm_group_label>Dose III - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or females subjects, 18-45 years (inclusive) of age at the time of
             enrollment.

          -  Females must be of non-childbearing potential (i.e., surgically sterile) or have to
             use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault
             cap with spermicide. Males should agree to abstain from sexual intercourse with a
             female partner or agree to use a condom/spermicide, in addition to having their female
             partner use some contraceptive measures.

          -  Clinically acceptable blood pressure and pulse rate in supine and standing position.
             Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.

          -  Body weight within normal range (Quetelet's index between 19 and 26) expressed as
             weight (kg) / height (m2).

          -  Able to understand the nature of the study and comply with all their requirements.

          -  Free acceptance to participate in the study by obtains signed informed consent form
             approved by the Ethics Committee of the Hospital (CEIC).

        Exclusion Criteria:

          -  History of serious adverse reactions or hypersensitivity to any drug.

          -  Presence or history of allergies requiring acute or chronic treatment (except seasonal
             allergic rhinitis).

          -  Background or clinical evidence of chronic diseases.

          -  Acute illness two weeks before drug administration.

          -  Having undergone major surgery during the previous 6 months.

          -  Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine
             patches, etc., for 6 months prior to the administration of the study medication

          -  History of alcohol dependence or drug abuse in the last 5 years or daily consumption
             of alcohol &gt; 40 g for men or 24 gr/day for women or high consumption of stimulating
             beverages (&gt; 5 coffees, teas or coca cola drinks/ day)

          -  Abnormal physical findings of clinical significance at the screening examination or
             baseline which would interfere with the objectives of the study.

          -  Need of any prescription medication within 14 days prior to the administration of the
             drug and non prescription medication or herbal medicines within 7 days prior to the
             administration of the drug.

          -  Participation in other clinical trials during the previous 90 days in which an
             investigational drug or a commercially available drug was tested.

          -  Having donated blood during 4 weeks period before inclusion in the study.

          -  Existence of any surgical or medical condition which might interfere with the
             absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or
             hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of
             pronounced constipation or diarrhea or conditions associated with total or partial
             obstruction of the urinary tract.

          -  12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥ 120 msec and QTc ≥ 440
             msec, bradycardia (&lt;50 bpm) or clinically significant minor ST wave changes or any
             other abnormal changes on the screening ECG that would interfere with measurement of
             the QT interval.

          -  Symptoms of a significant somatic or mental illness in the four week period preceding
             drug administration.

          -  History of hepatitis HBV and / or HCV and / or positive serology results which
             indicate the presence of hepatitis B surface antigen and / or detectable HCV
             ribonucleic acid (RNA).

          -  Positive results from the HIV serology.

          -  Clinically significant abnormal laboratory values (as determined by the Principal
             Investigator) at the screening evaluation.

          -  Positive results of the drugs at screening period or the day before starting treatment
             period. A minimum list of drugs that will be screened for include Amphetamines,
             Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be
             repeated at the discretion of the Principal Investigator).

          -  Known hypersensitivity to the study drug or the composition of the galenical form.

          -  History of psychiatric diseases or epileptic seizures

          -  Females with positive results from the pregnancy test or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Martínez Colomer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIM Sant Pau - I.I.B. Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palobiofarma S.L. (molecule owner)</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08302</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIM Sant Pau - I.I.B. Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenosine A2a receptor antagonist</keyword>
  <keyword>adenosine receptor modulator</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

